Exane Derivatives’s Axalta AXTA Stock Holding History

Exane Derivatives’s Portfolio AXTA Stock Details AXTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-355	Closed	-$10.6K	–	1050
2021 Q2	$10.6K	Sell	355 -15,167	-98%	-$480K	﹤0.01%	740
2021 Q1	$459K	Buy	+15,522	New	+$445K	0.13%	159

Other funds holding AXTA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

SCM

Shapiro Capital Management Atlanta, Georgia $1.6B AUM 13.27% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Rivulet Capital Summit, New Jersey $91.2M AUM 6.8% 1-Year Est. Return

RRAM

River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return

Exane Derivatives's AXTA Position: Q3 2021 in Review

Exane Derivatives sold out of Axalta (AXTA) in Q3 2021, closing a stake of 355 shares — an estimated $10.6K sold.

Exane Derivatives first reported a position in AXTA in Q1 2021 and held it in 2 quarters. The position peaked at $459K in Q1 2021. 309 funds tracked by Wall St. Rank hold AXTA as of Q3 2021.

Exane Derivatives reported no remaining Axalta position as of Q3 2021 after selling out during the quarter.
Exane Derivatives sold 355 Axalta shares in Q3 2021, an estimated $10.6K.
Exane Derivatives first reported a position in Axalta in Q1 2021 and held it in 2 quarters.
Exane Derivatives's Axalta position peaked at $459K in Q1 2021.
309 funds tracked by Wall St. Rank held Axalta as of Q3 2021.

Based on Exane Derivatives's 13F filing for Q3 2021, filed 26 Oct 2021.